ABN: 91 064 820 408



US: 350 W Phillips Road Greer, SC 29650 USA

AU: Level 7, 330 Collins Street Melbourne, Victoria, 3000

ASX | 31 March 2023

Amended Appendix 3Y

Sydney (Australia), Greer (South Carolina, US) – 31 March 2023: Alexium International Group Limited (ASX: AJX) wishes to correct an administrative error in the Appendix 3Y issued on 1 November 2021 in respect to the securities held by Dr Robert Brookins.

The Company on 26 October 2021, issued an Appendix 3G for the issue of Ordinary Shares resulting from a conversion of Performance Rights, which was subsequently corrected by way of lodging an Appendix 2A on 1 December 2021. While that Appendix 2A correctly stated the number of Ordinary Shares to Dr Brookins, due to an administrative oversight, the Company did not lodge an updated Appendix 3Y identifying the conversion of these securities in Dr Brookins' holdings.

The Company therefore wishes to issue the **attached** revised Appendix 3Y which correctly states the number of securities held by Dr Brookins' which also includes the recent issue and allotment of 13,377,148 Share Appreciation Rights (SARs) to Dr Brookins as approved at the 2022 Annual General Meeting (Resolutions 4 and 5).

In accordance with ASX Listing Rules 3.19A.2 and 3.19B, the Company confirms that it has undertaken a review of its procedures to ensure that all future Appendices 3X, 3Y and 3Z are issued on time and contain the correct information.

ENDS

Authorised for release by the Chief Financial Officer of Alexium International Group Limited.

About Alexium International Group Limited

Alexium International Group Limited (ASX: AJX) is a performance chemicals provider for advanced materials applications with a focus on flame retardancy and thermal management. The Company is driven by an innovation model for addressing market gaps with patent-protected technologies. These environmentally friendly solutions have applications for several industries and can be customized to meet customer needs. Key markets for Alexium are military uniforms, workwear, and bedding products. Alexium brands include Alexicool[®] and Alexiflam[®]. For additional information about Alexium, please visit <u>www.alexiuminternational.com</u>.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Alexium International Group
ABN	91 064 820 408

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Robert Brookins
Date of last notice	1 November 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Not applicable	
Date of change	31 March 2023	
No. of securities held prior to change	5,262,638 Ordinary Shares 6,505,703 Share Appreciation Rights	
Class	Share Appreciation Rights	
Number acquired	6,871,445ShareAppreciationRights(Resolution 4, 2022 AGM NOM); and6,505,703ShareAppreciationRights(Resolution 5, 2022 AGM NOM)	
Number disposed	Not applicable	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil consideration	

⁺ See chapter 19 for defined terms.

No. of securities held after change	5,262,638 Ordinary Shares	
	19,882,851 Share Appreciation Rights	
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Share Appreciation Rights following shareholder approval at the 2022 Annual General Meeting.	

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed	N/A
above traded during a ⁺ closed period where prior written	
clearance was required?	
If so, was prior written clearance provided to allow the	N/A
trade to proceed during this period?	
If prior written clearance was provided, on what date was	N/A
this provided?	

⁺ See chapter 19 for defined terms.